(ZLAB) Zai Lab - Ratings and Ratios
Exchange: NASDAQ • Country: China • Currency: USD • Type: Common Stock • ISIN: US98887Q1040
ZLAB: Cancer, Autoimmune, Infectious, Neuroscience
Zai Lab Ltd (NASDAQ:ZLAB) is a biotechnology company focused on developing and commercializing innovative therapies across multiple therapeutic areas, including oncology, autoimmune disorders, infectious diseases, and neuroscience. With a strong emphasis on addressing unmet medical needs, Zai Lab has established a diverse portfolio of both commercialized products and investigational therapies.
The companys commercial products include Zejula, a poly polymerase 1/2 inhibitor for ovarian cancer; Optune, a Tumor Treating Fields (TTFields) therapy that uses low-intensity, alternating electric fields to treat glioblastoma; NUZYRA, a novel antibiotic for acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; Qinlock, a tyrosine kinase inhibitor for gastrointestinal stromal tumors; and VYVGART, an antibody fragment for the treatment of myasthenia gravis. These products underscore Zai Labs commitment to bringing differentiated treatments to patients with serious diseases.
Zai Labs pipeline is equally impressive, with a focus on precision oncology and innovative modalities. Key development programs include Repotrectinib, a next-generation TKI targeting ROS1 and TRK A/B/C in cancer patients; Tisotumab vedotin, an antibody-drug conjugate for cancer treatment; Adagrasib, a KRAS-G12C inhibitor with potential across multiple solid tumors; and Bemarituzumab, a monoclonal antibody targeting gastric and gastroesophageal junction cancer. The company is also advancing Sulbactam/durlobactam, a beta-lactam antibiotic combination for serious infections caused by Acinetobacter, and KarXT, a novel psychiatry and neuroscience drug candidate.
A key aspect of Zai Labs strategy is its extensive network of collaborations with global biopharma leaders. These partnerships include agreements with Tesaro, NovoCure, Deciphera, Paratek, argenx, BMS, Mirati, Amgen, Innoviva, and Karuna, among others. These collaborations not only enhance Zai Labs pipeline but also demonstrate its ability to identify and execute on high-value opportunities. Additionally, the company has entered into a strategic collaboration with Pfizer for XACDURO, further expanding its reach in infectious diseases.
Founded in 2013 and headquartered in Shanghai, China, Zai Lab has rapidly established itself as a leader in the biotechnology sector. Its focus on innovation, strategic partnerships, and addressing significant unmet medical needs positions it well for long-term growth. With a market capitalization of approximately $2.96 billion USD and a price-to-book ratio of 4.54, Zai Lab offers investors exposure to a high-growth biotech company with a strong pipeline and commercial execution capabilities.
Additional Sources for ZLAB Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ZLAB Stock Overview
Market Cap in USD | 4,045m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2017-09-20 |
ZLAB Stock Ratings
Growth 5y | -14.1% |
Fundamental | -32.0% |
Dividend | 0.0% |
Rel. Strength Industry | 125 |
Analysts | 4.73/5 |
Fair Price Momentum | 43.26 USD |
Fair Price DCF | - |
ZLAB Dividends
No Dividends PaidZLAB Growth Ratios
Growth Correlation 3m | 81.3% |
Growth Correlation 12m | 87.1% |
Growth Correlation 5y | -85.1% |
CAGR 5y | -3.02% |
CAGR/Max DD 5y | -0.03 |
Sharpe Ratio 12m | 1.08 |
Alpha | 87.41 |
Beta | 0.58 |
Volatility | 67.85% |
Current Volume | 1027.8k |
Average Volume 20d | 1399.1k |
As of March 17, 2025, the stock is trading at USD 38.20 with a total of 1,027,778 shares traded.
Over the past week, the price has changed by +10.12%, over one month by +23.50%, over three months by +45.91% and over the past year by +111.28%.
Probably not. Based on ValueRay Fundamental Analyses, Zai Lab (NASDAQ:ZLAB) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -32.02 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ZLAB as of March 2025 is 43.26. This means that ZLAB is currently undervalued and has a potential upside of +13.25% (Margin of Safety).
Zai Lab has received a consensus analysts rating of 4.73. Therefor, it is recommend to buy ZLAB.
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ZLAB Zai Lab will be worth about 48 in March 2026. The stock is currently trading at 38.20. This means that the stock has a potential upside of +25.6%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 54.3 | 42% |
Analysts Target Price | 52.4 | 37.1% |
ValueRay Target Price | 48 | 25.6% |